“The Metastatic Prostate Cancer market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period (2023-2032). Furthermore, launching various multiple- Metastatic Prostate Cancer pipeline products will significantly revolutionize the Metastatic Prostate Cancer market dynamics”
The Metastatic Prostate Cancer market report provides current treatment practices, Metastatic Prostate Cancer emerging drugs, market share of individual therapies, and current and forecasted 7MM Metastatic Prostate Cancer market size from 2019 to 2032. The report also covers current Metastatic Prostate Cancer treatment market practices/algorithms and unmet medical needs to curate the best opportunities and assess the market’s underlying potential.
Key Takeaways from the Metastatic Prostate Cancer Market Research Report
- As per DelveInsight estimates, the total Metastatic Prostate Cancer prevalent population in the 7MM was nearly 7,977,000 cases in 2022. The cases in the 7MM are expected to increase during the study period, i.e., 2019–2032.
- As per DelveInsight estimates, Metastatic Prostate Cancer treated cases in Japan were roughly 25,000 in 2022.
- The leading companies working in the Metastatic Prostate Cancer Market include AstraZeneca, Bayer, Janssen Research & Development LLC, ImaginAb Inc., Astellas Pharma Inc., ORIC Pharmaceuticals, Genentech Inc., Epic Sciences, Pfizer, Bristol-Myers Squibb, Bayer, MedImmune LLC, Arvinas Inc., Sanofi, Hoffmann-La Roche, Sun Pharmaceutical Industries Limited, Telix International Pty Ltd, Takeda, Modra Pharmaceuticals, Saladax Biomedical Inc, and others.
- Promising Metastatic Prostate Cancer Pipeline Therapies in the various stages of development include AZD5305, Enzalutamide, Abiraterone Acetate, Darolutamide, ORIC-944, RO7656594, Sunitinib, and others.
- September 2023: Hoffmann-La Roche announced a study of phase 3 clinical trials for Ipatasertib, Abiraterone, and Prednisone/Prednisolone. The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of ipatasertib plus abiraterone and prednisone/prednisolone compared with placebo plus abiraterone and prednisone/prednisolone in participants with metastatic castrate-resistant prostate cancer (mCRPC).
- September 2023: Ipsen announced a study of phase 3 clinical trials for Triptorelin pamoate (embonate) salt. The main aim of this study is to assess the effectiveness and safety of the 6-month formulation of triptorelin pamoate in Chinese participants with locally advanced or metastatic cancer of the prostate. Participants will receive 1 injection of triptorelin pamoate 6-month formulation.
Discover more about therapies set to grab major Metastatic Prostate Cancer Market Share @ Metastatic Prostate Cancer Market Size
Metastatic Prostate Cancer Overview
Prostate cancer is a type of malignancy that occurs in the prostate gland, which is a part of male reproductive system. Prostate cancer is the 3rd most prevalent type of cancer in the US and the fourth most common worldwide. Approximately 1 in 9 men in the US will be diagnosed with prostate cancer at some point in their lives.
Metastatic Prostate Cancer Epidemiology Segmentation in the 7MM
- Total Metastatic Prostate Cancer prevalent cases
- Total Metastatic Prostate Cancer diagnosed cases
- Metastatic Prostate Cancer Age-specific cases
- Total Metastatic Prostate Cancer diagnosed cases of prostate cancer by clinical stages,
- Total Metastatic Prostate Cancer treated cases
Download the report to understand which factors are driving Metastatic Prostate Cancer Epidemiology Trends @ Metastatic Prostate Cancer Epidemiological Insights
Metastatic Prostate Cancer Marketed Drugs
- XTANDI (enzalutamide): Astellas Pharma/Pfizer
- ERLEADA (apalutamide): Janssen Pharmaceutical
Metastatic Prostate Cancer Emerging Drugs
- MGC018 (vobramitamab duocarmazine): MacroGenics
- Bavdegalutamide (ARV-110): Arvinas
To learn more about Metastatic Prostate Cancer Treatment options, visit @ Metastatic Prostate Cancer Drugs
Metastatic Prostate Cancer Market Outlook
Metastatic CSPC, also referred to as mHSPC in literature refers to prostate cancer that still responds to testosterone suppression therapy. Metastatic Prostate Cancer is another type of prostate cancer that is highly talked about and holds huge market potential. It is a stage of prostate cancer that has spread to other parts of the body, such as lymph nodes or bones, and no longer responds to treatment that lowers testosterone. Moreover, patients with newly diagnosed metastatic disease and high-risk disease characteristics tend to have a poorer prognosis.
Metastatic Prostate Cancer Drugs Market
Metastatic Prostate Cancer drugs can be used in the treatment algorithm for metastatic prostate cancer, but the standard of care continues to be androgen deprivation therapy with either docetaxel, enzalutamide (XTANDI), apalutamide (ERLEADA), or abiraterone acetate (ZYTIGA). Additionally, darolutamide (NUBEQA) could potentially be added to this treatment. The established markets of the already approved drugs may provide a fair competition to the upcoming therapies.
Learn more about the Metastatic Prostate Cancer Pipeline Therapies in clinical trials @ Metastatic Prostate Cancer Market Landscape
Scope of the Metastatic Prostate Cancer Market Research Report
- Coverage- 7MM
- Study Period- 2019-2032
- Metastatic Prostate Cancer Companies- AstraZeneca, Bayer, Janssen Research & Development LLC, ImaginAb Inc., Astellas Pharma Inc., ORIC Pharmaceuticals, Genentech Inc., Epic Sciences, Pfizer, Bristol-Myers Squibb, Bayer, MedImmune LLC, Arvinas Inc., Sanofi, Hoffmann-La Roche, Sun Pharmaceutical Industries Limited, Telix International Pty Ltd, Takeda, Modra Pharmaceuticals, Saladax Biomedical Inc, and others.
- Metastatic Prostate Cancer Pipeline Therapies- AZD5305, Enzalutamide, Abiraterone Acetate, Darolutamide, ORIC-944, RO7656594, Sunitinib, and others.
- Metastatic Prostate Cancer Market Dynamics: Metastatic Prostate Cancer Market Drivers and Barriers
- Metastatic Prostate Cancer Market Access and Reimbursement, Unmet Needs, and Future Perspectives
Discover more about Metastatic Prostate Cancer Drugs in development @ Metastatic Prostate Cancer Ongoing Clinical Trials Analysis
Table of Content
1. Key Insights
2. Report Introduction
3. Metastatic Prostate Cancer Market Overview at a Glance
4. Executive Summary of Metastatic Prostate Cancer
5. Key Events
6. Epidemiology and Market Forecast Methodology
7. SWOT Analysis
8. Disease Background and Overview
9. Diagnosis of Prostate Cancer
10. Treatment and Management of Prostate Cancer
11. American Urological Association (AUA) Guidelines for Metastatic Prostate Cancer: 2023
12. Guidelines for Metastatic Prostate Cancer: Abiraterone acetate combined with castration is another standard (European Association of Urology, 2023)
13. National Institute for health and care excellence (NICE) Recommendation Guidelines for Metastatic Prostate Cancer: 2023
14. SEOM Clinical Guidelines for Metastatic Prostate Cancer: 2023
15. Updated NCCN Guidelines for Metastatic Prostate Cancer
16. Epidemiology and Patient Population
17. Organizations contributing towards Metastatic Prostate Cancer
18. Marketed Therapies
19. Emerging Therapies
20. Metastatic Prostate Cancer: Seven Major Market Analysis
21. Metastatic Prostate Cancer Market Drivers
22. Metastatic Prostate Cancer Market Barriers
23. Metastatic Prostate Cancer Unmet Needs
24. Reimbursement and Market Access
26. Report Methodology
27. DelveInsight Capabilities
29. About DelveInsight
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Healthcare Market Research Reports, Competitive Landscaping, and Mergers and acquisitions.
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States